.86;
P < .05), MALE-POD (HR, 0.28; 95% CI,
0.13-0.63; P < .05), and primary
patency loss (HR, 0.25; 95% CI,
0.10-0.58; P < .05)

Retrospective, multiinstitutional registry
study; moderate
methodologic quality

